MA50030A - Traitement du cancer par stimulation de la production d'il-12 - Google Patents

Traitement du cancer par stimulation de la production d'il-12

Info

Publication number
MA50030A
MA50030A MA050030A MA50030A MA50030A MA 50030 A MA50030 A MA 50030A MA 050030 A MA050030 A MA 050030A MA 50030 A MA50030 A MA 50030A MA 50030 A MA50030 A MA 50030A
Authority
MA
Morocco
Prior art keywords
stimulating
production
cancer treatment
cancer
treatment
Prior art date
Application number
MA050030A
Other languages
English (en)
Inventor
Stephen Mark Anderton
Clare Louise Doris
David Festus Charles Moffat
Martin John Perry
Original Assignee
Macrophage Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrophage Pharma Ltd filed Critical Macrophage Pharma Ltd
Publication of MA50030A publication Critical patent/MA50030A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
MA050030A 2017-08-31 2018-08-30 Traitement du cancer par stimulation de la production d'il-12 MA50030A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1713975.9A GB201713975D0 (en) 2017-08-31 2017-08-31 Medical use

Publications (1)

Publication Number Publication Date
MA50030A true MA50030A (fr) 2020-07-08

Family

ID=60050569

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050030A MA50030A (fr) 2017-08-31 2018-08-30 Traitement du cancer par stimulation de la production d'il-12

Country Status (15)

Country Link
US (1) US11382902B2 (fr)
EP (1) EP3675851A1 (fr)
JP (1) JP2020536848A (fr)
KR (1) KR20200129086A (fr)
CN (1) CN111356457A (fr)
AU (1) AU2018326668A1 (fr)
BR (1) BR112020003033A2 (fr)
CA (1) CA3071550A1 (fr)
GB (1) GB201713975D0 (fr)
IL (1) IL272769A (fr)
MA (1) MA50030A (fr)
MX (1) MX2020001197A (fr)
RU (1) RU2020111355A (fr)
SG (1) SG11202000565VA (fr)
WO (1) WO2019043389A1 (fr)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
FR2790960B1 (fr) * 1999-03-15 2002-10-31 Pf Medicament Utilisation de fractions membranaires bacteriennes a activite immunostimulante dans le traitement de cancers, leurs procedes de preparation et les compositions pharmaceutiques les contenant
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
ATE375980T1 (de) 2002-02-12 2007-11-15 Smithkline Beecham Corp Nicotinamide und deren verwendung als p38 inhibitoren
EP1487794A1 (fr) 2002-03-14 2004-12-22 Bayer Aktiengesellschaft Aroylpyridinones monocycliques tenant lieu d'agents anti-inflammatoires
US20060079461A1 (en) * 2003-12-24 2006-04-13 Scios, Inc. Treatment of multiple myeloma by inhibition of p38 MAP kinase
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
AU2006243000B2 (en) 2005-05-05 2011-05-26 Macrophage Pharma Limited Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
GB0608821D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd DHFR enzyme inhibitors
GB0608823D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of P13 kinase
GB0608837D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of MAP kinase
EP2013175B9 (fr) 2006-05-04 2020-11-11 Macrophage Pharma Limited INHIBITEURS DE PROTÉINE-KINASE ASSOCIÉE AUX MEMBRANES p38
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
EA200900593A1 (ru) 2006-10-25 2010-06-30 Хрома Терапьютикс Лтд. Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака
GB0621203D0 (en) 2006-10-25 2006-12-06 Chroma Therapeutics Ltd PLK inhibitors
WO2008053131A1 (fr) 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates en tant qu'inhibiteurs de l'histone désacétylase
WO2008053182A1 (fr) 2006-11-01 2008-05-08 Chroma Therapeutics Ltd. INHIBITEURS DE LA SÉRINE-THRÉONINE PROTÉINE KINASE IKK-β
JP2010508337A (ja) 2006-11-01 2010-03-18 クロマ セラピューティクス リミテッド Ｉｋｋ−ベータセリン−スレオニンプロテインキナーゼの阻害剤
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
US20100267774A1 (en) 2007-11-07 2010-10-21 Chroma Therapeutics Ltd. P38 map kinase inhibitors
JP5555186B2 (ja) 2008-02-29 2014-07-23 クロマ セラピューティクス リミテッド ｐ３８ＭＡＰキナーゼ阻害剤
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
EP2297128B1 (fr) 2008-04-23 2012-08-15 Chroma Therapeutics Ltd. Inhibiteurs de sérine-thréonine protéine kinase ikk-
GB0807451D0 (en) 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
MX2010011643A (es) 2008-04-26 2010-11-30 Chroma Therapeutics Ltd Tiofencarboxamidas sustituidas como inhibidores de la proteina cinasa ikk-beta serina, treonina.
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB0907120D0 (en) 2009-04-24 2009-06-03 Chroma Therapeutics Ltd Inhibitors of IKK-ß serine-threonine protein kinase
GB201009853D0 (en) 2010-06-11 2010-07-21 Chroma Therapeutics Ltd HSP90 inhibitors
GB201021467D0 (en) 2010-12-17 2011-02-02 Chroma Therapeutics Ltd Imaging agents
WO2013057281A2 (fr) * 2011-10-21 2013-04-25 Transgene Sa Modulation de l'activation des macrophages
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
PL3222616T3 (pl) * 2012-10-17 2019-12-31 Macrophage Pharma Limited N-[2-{4-[6-amino-5-(2,4-difluorobenzoilo)-2-oksopirydyn-1(2h)-ylo]-3,5-difluorofenylo}etylo)-L-alaninian tert-butylu lub jego sól, hydrat lub solwat
GB201306901D0 (en) 2013-04-16 2013-05-29 Chroma Therapeutics Ltd Combination

Also Published As

Publication number Publication date
RU2020111355A (ru) 2021-09-30
IL272769A (en) 2020-04-30
MX2020001197A (es) 2020-08-13
AU2018326668A1 (en) 2020-02-20
CN111356457A (zh) 2020-06-30
KR20200129086A (ko) 2020-11-17
US20200360359A1 (en) 2020-11-19
JP2020536848A (ja) 2020-12-17
BR112020003033A2 (pt) 2020-08-04
GB201713975D0 (en) 2017-10-18
RU2020111355A3 (fr) 2021-12-16
US11382902B2 (en) 2022-07-12
WO2019043389A1 (fr) 2019-03-07
EP3675851A1 (fr) 2020-07-08
CA3071550A1 (fr) 2019-03-07
SG11202000565VA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
EP3813647A4 (fr) Stimulation multimodale de traitement des tremblements
IL283838A (en) Method of treating cancer with a cancer therapy in combination with another therapeutic agent
IL269026A (en) Methods of treating tumor
EP3618829A4 (fr) Dérivés de quinazoline-pyridine pour le traitement de troubles associés à un cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
PL3455258T3 (pl) Sposoby leczenia nowotworu skóry przez podawanie inhibitora pd-1
EP3448263A4 (fr) Traitement électrothérapeutique
SMT202200199T1 (it) Metodi di trattamento del cancro del seno ar+.
IL275543A (en) Intratubular methods for the treatment of breast disorders
LT3458610T (lt) Krūties vėžio terapinis gydymas, remiantis c-maf būkle
MA47408A (fr) Traitement du cancer
EP3610026A4 (fr) Méthodes de traitement du cancer de la vessie
IL265938A (en) Lasofoxifene treatment of er+ breast cancer
MA53553A (fr) Traitement post-chirurgical de la douleur
MA44612A (fr) Méthodes de traitement de cancers pédiatriques
EP3470111C0 (fr) Stimulation du nerf vague pour traiter des troubles neurodégénératifs
WO2015197193A3 (fr) Nouvelle utilisation de molécules inhibitrices de jnk pour le traitement de diverses maladies
HUE059387T2 (hu) Parkinson-kór kezelése
IL254173B (en) Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy
EP3733175A4 (fr) Traitement du cancer
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
FR3039368B1 (fr) Procede de traitement cosmetique
IL281600A (en) Methods of treating cancer
EP3787625A4 (fr) Méthodes de traitement du cancer
IL270900A (en) Treatment of cutaneous disorders